ABSTRACT:
BACKGROUND INFORMATION: Combination of antihypertensive therapy with an inhibitor of the renin-angiotensin system (RAS) and a calcium channel blocker (CCB) is a rational approach to achieve blood pressure (BP) goals in patients with hypertension, and may provide additional cardiovascular protection compares to others strategies in special population. This article reviews the rationale for, and evidence supporting, the use of newer fixed-dose combinations of RAS inhibitors and CCBs with particulars emphasis on perindopril/ amlodipine. METHODS: A total of 120 patients enrolled in the study from general medicine department in tertiary care hospital. The document data were evaluated for use of comparative efficacy between amlodipine + metoprolol, amlodipine + atenolol, amlodipine + enalapril. RESULTS: A total of 120 hypertension patients were included in the study. All those who were included in the study were from <40 to > 70 years. In the study out of 120 patients 2.52% of patients were in the age of less than 40 years, 11.6% of patients were in the group of 41-50 years, 21.66% of patients were age group of 51-60 years, 34.16% of patients were in the age group of 61-70years and 30% of patients were in the age group of more than 70 years. Based on the combination therapies the patients were divided into two groups. Totally 60 patients in each group. Each group has a more patients ratio between the age groups of 51-60 and 61-70. CONCLUSION: Overall the study results conclude that a combination of amlodipine with atenolol therapy have greater impact on control BP, when compared with amlodipine + metoprolol , amlodipine + enalapril therapies. The benefits were more with combinational therapy in comparison to monotherapy.